Prior to forming FIR Capital, Guilherme was the Chairman of Biobras S.A..
Under Guilherme´s leadership, Biobras grew from a start-up to become the world´s 4th largest insulin producer.
Among its other achievements, Biobras consistently ranked as one of the top five performing stocks on the Sao Paulo Stock Exchange´s BOVESPA index and was the best performing investment ever made by BNDES, Brazil´s National Economic Development Bank.
Competing head-to-head with pharmaceutical giants such as Eli Lilly, Novo Nordisk and Aventis, Biobras became the leading player in the Brazilian insulin market before its sale to Novo Nordisk in 2001.
Along the way, Biobras distinguished itself on the technology front by successfully developing and patenting its own process for producing recombinant human insulin.
Guilherme also played an important role in the formation of the Biominas Foundation, a thriving biotechnology cluster that is the largest in Latin America and one of the largest in the world, comparable to North Carolina´s Triangle Research Park.
Guilherme was nominated by the President of Brazil to serve on the National Council of Science and Technology and is a member of the board of directors of the Dom Cabral Foundation, the leading management development institute for top corporations and entrepreneurs in Brazil.
Guilherme is a former Chairman and Board Member of the International Chamber of Commerce of Brazil, and currently serves as the Honorary Consul of the Republic of Russia in Belo Horizonte.
Guilherme also serves as a member of the international Board of Directors of INSEAD in Brazil and on the board of directors of several FIR Capital portfolio companies.